Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026

Data ReadoutpositiveatuzaginstatPositive

AI Analysis

Summary

Lighthouse Pharmaceuticals announced positive Phase 2/3 GAIN trial data for atuzaginstat, a gingipain inhibitor, demonstrating benefits in neuropsychiatric symptoms and reduced caregiver distress in P. gingivalis-positive Alzheimer's Disease patients.

Clinical Trial Data

Phase

2/3

Primary Endpoint

Met

Outcome Details

Phase 2/3 GAIN trial demonstrating benefits in neuropsychiatric symptoms and caregiver distress reduction in P. gingivalis-positive Alzheimer's Disease patients

Importance:6/10

Sentiment:

0.70

Alzheimer's Diseasegingipain inhibitorPorphyromonas gingivalisneuropsychiatric symptomsAAIC 2026

Related Companies

$INTI

Read the original article

Published by PR Newswire Biotech on July 13, 2026 8:00 AM

Read Original